NASDAQ · JBIO
Healthcare · Biotechnology
$14.42
Down-$0.31 (-2.10%)
Updated Sep 28, 2026, 4:00 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
JBIO closed at $14.42 after 19 trading sessions, down 32.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $14.81 | $15.2015 | $14.39 | $14.42 | 525.82K |
| Sep 24, 2026 | $14.59 | $15.06 | $14.45 | $14.73 | 1.05M |
| Sep 23, 2026 | $16.64 | $16.64 | $14.58 | $14.71 | 1.46M |
| Sep 22, 2026 | $16.92 | $17.16 | $16.60 | $16.76 | 643.92K |
| Sep 21, 2026 | $17.12 | $17.67 | $16.49 | $16.74 | 528.78K |
| Sep 18, 2026 | $17.15 | $17.35 | $16.79 | $16.94 | 2.94M |
| Sep 17, 2026 | $17.03 | $17.74 | $16.94 | $17.14 | 815.84K |
| Sep 16, 2026 | $17.52 | $17.61 | $16.16 | $16.65 | 1.73M |
| Sep 15, 2026 | $18.16 | $18.16 | $17.02 | $17.38 | 849.77K |
| Sep 14, 2026 | $18.06 | $18.83 | $17.88 | $18.18 | 829.51K |
| Sep 11, 2026 | $19.38 | $20.10 | $17.53 | $17.89 | 1.25M |
| Sep 10, 2026 | $18.82 | $19.33 | $18.59 | $19.14 | 1.22M |
| Sep 9, 2026 | $19.43 | $19.98 | $18.79 | $19.06 | 1.51M |
| Sep 8, 2026 | $19.67 | $20.15 | $19.002 | $19.45 | 825.6K |
| Sep 4, 2026 | $19.86 | $20.35 | $19.70 | $19.90 | 605.02K |
| Sep 3, 2026 | $21.00 | $21.265 | $19.76 | $19.85 | 1.38M |
| Sep 2, 2026 | $21.17 | $22.00 | $20.475 | $21.40 | 506.17K |
| Sep 1, 2026 | $21.32 | $21.615 | $20.73 | $21.02 | 516.64K |
| Aug 31, 2026 | $20.65 | $21.45 | $20.35 | $21.36 | 837.04K |
The latest Smart Investors Daily articles mentioning JBIO.
JBIO research
Company profile and research snapshot.
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Wedbush | Outperform | — |
| Aug 10, 2026 | BTIG | Buy | — |
| Jun 15, 2026 | UBS | Buy | — |
| Jun 2, 2026 | Wedbush | Outperform | — |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Jade Biosciences, Inc. (JBIO) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 9:20 AM EDTCompany ParticipantsTom Frohlich - President,...
Yahoo · Sep 1, 2026
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Tuesday, September 8 at 3:45 p.m. ETCiti 2026 Biopharma Back to School Summit Fireside Chat: Wednesday, Septe
SeekingAlpha · Aug 19, 2026
Jade Biosciences targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence. Read more on JBIO stock here.
Benzinga · Aug 11, 2026
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $45 to $47.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning JBIO.
